The Bridge Program equips researchers and entrepreneurs with the knowledge, skills and networks to enable the successful commercialisation of new pharmaceuticals. Delivered by Queensland University of Technology, the Bridge Program is funded by MTPConnect and a consortium of 10 pharmaceutical companies and universities.
Launched in 2017, the program selects 100 participants annually from across Australia to take part in face-to-face and online training in the various components that contribute to the commercialisation of new medicines. Covering the scientific, legal, financial, clinical, regulatory and reimbursement elements of pharmaceutical commercialisation, the program is available to researchers, entrepreneurs and associated professionals from the pharmaceutical ecosystem around Australia.
The tacit industry knowledge that the Bridge Program consortium provides makes the program unique in its integration into venture capital and global pharmaceutical networks and its ability to share specific, detailed and practical know-how. Participants benefit from direct exposure to networking opportunities at the 3-day Symposium, which ties together the program learning and enables collaboration and commercialisation opportunities.
The Bridge Program was awarded industry matched funding through the MTPConnect Project Fund Program, to deliver an education program that provides the necessary training to enable successful commercialisation of Australian pharmaceutical discoveries. In 2019, MTPConnect’s Biomedical Translation Bridge (BTB) Fund also awarded funding for the Bridge Program to continue to up-skill researchers and entrepreneurs and propel the Australian pharmaceutical research sector to the global stage. More information available on the BTB here.
Outcomes: Since commencement in 2017 the Bridge program has now delivered 4 cohorts of trainees. Together the Bridge and Bridge Tech program has resulted in 31 patents, 29 start-up companies and 26 clinical trials.
|Consortium Lead||Queensland University of Technology|
|Consortium Members||Abbvie, Amgen, CSL Limited, Janssen-Cilag, Macquarie University, Medicines Australia, MSD Australia, Pfizer & Novartis|
|Project duration||March 2017 - December 2019 (Completed)|
|Contact||Justine McEvoy, Project Officer, The Bridge Program - email@example.com|
Listen to the MTPConnect Podcast to hear from QUT Executive Director Lyn Griffiths talk about the program